STM Blog
Finding the Missing Piece: One man’s journey to a von Willebrand disease diagnosis
Frank, a 65-year-old man, spent decades suffering from von Willebrand disease (VWD) without a diagnosis. His journey, marked by severe bleeds and uncertainty, changed when his granddaughter was diagnosed with VWD. This discovery led to Frank’s diagnosis and treatment with VONVENDI, which allows him to better manage his condition and regain control of his life.
Last Updated on October 19, 2025 by Daily News Staff
Finding the Missing Piece: One man’s journey to a von Willebrand disease diagnosis
(Family Features) “I wanted to live my life like there was nothing wrong, but the fear was always there.”
That’s how 65-year-old Frank described life with von Willebrand disease (VWD), the most common bleeding disorder, affecting more than 3 million Americans.
For Frank, the signs started early with nosebleeds so severe they seemed unstoppable. In his 30s, one gastrointestinal bleed required nearly 7 pints of blood to stabilize him – a staggering amount, considering most adults only have 8-12 pints total.
Life with VWD can mean living in constant uncertainty. Any injury, surgery or even simple dental procedure can trigger a dangerous bleed. Symptoms like frequent bruising or heavy menstrual bleeding in women can affect quality of life. The consequences for Frank, even before his diagnosis, were often urgent and life-threatening.
Hospital visits and bleeds became routine, draining both his body and spirit. Frank lost weight, struggled with temperature swings and each trip home from the hospital felt like borrowed time before his next bleeding episode.
Eventually, his body began rejecting the blood transfusions meant to treat him during these mysterious bleeding episodes – a complication known as hemolytic anemia. With few options left, Frank and his partner, Carla, faced a future filled with fear and uncertainty, unsure how much longer his body could keep going.
Journey to a Diagnosis
Like many living with VWD, Frank spent years searching for answers – managing symptoms without understanding their cause. Bleeds came without warning. Triggers were a mystery. A diagnosis felt out of reach.
Through it all, Frank and Carla were their own fiercest advocates. Carla became his second set of eyes and ears by researching symptoms, writing down questions and sitting beside him in countless exam rooms.
“I realized when he was in the hospital, I must be there with him,” Carla said. “I needed to be there when the doctors and the nurses were talking to him. I slept in his room to be there for morning rounds to make sure everyone had the correct information.”
For years, they pressed on without answers or an official diagnosis until 2013, when everything changed.
Frank’s granddaughter was diagnosed with VWD, which they learned is a hereditary bleeding disorder. In that moment, something clicked. After decades of uncertainty, Frank finally had a clue and a connection.
He and Carla immediately sought out VWD education. Testing confirmed what they suspected: Frank had been living with VWD all along.
“Getting the diagnosis was a turning point,” Frank said. “For the first time, we weren’t just waiting for the next bleed – we finally had a way to take control.”
A Path Forward
Frank finally found hope and a path forward. After discussing which treatment option may be right for him with his health care team, Frank began using VONVENDI® [von Willebrand factor (Recombinant)] on-demand to treat and control his bleeding episodes.
VONVENDI is the only von Willebrand factor (VWF) treatment made without human blood or plasma with approved uses in both adults and children with VWD. For someone whose body had begun rejecting transfusions, having a recombinant option was important. But more than that – it worked for Frank.
“Since starting VONVENDI, I feel like I finally found the right path forward for me,” Frank said. “I can control my bleeds when they happen, and I have a plan in place to treat the next one.”
The U.S. Food and Drug Administration recently approved an expanded indication for VONVENDI, which is now indicated for adults and children with VWD to treat and control bleeding episodes (on-demand), to prevent excessive bleeding during and after surgery (perioperative) and for adult patients only, to reduce the number of bleeding episodes when used regularly (prophylaxis). Please see below for Detailed Important Risk Information or click here for the full Prescribing Information.
With this expanded indication, VONVENDI can now help more patients like Frank – not just control bleeds but also try to prevent them. Frank and Carla know there’s no cure, but for the first time in a long time, they have a plan to address Frank’s VWD bleeds.
Visit VONVENDI.com or speak with your doctor to learn more about VWD and discuss if treatment may be right for you.
VONVENDI [von Willebrand factor (Recombinant)] Important Information
What is VONVENDI?
VONVENDI is used in adults and children with von Willebrand disease to:
- treat and control bleeding episodes
- prevent excessive bleeding during and after surgery
For adult patients only:
- reduce the number of bleeding episodes when used regularly (prophylaxis)
Detailed Important Risk Information
Who should not use VONVENDI?
You should not use VONVENDI if you:
- Are allergic to any ingredients in VONVENDI.
- Are allergic to mice or hamsters.
Tell your healthcare provider if you are pregnant or breastfeeding because VONVENDI may not be right for you.
How should I use VONVENDI?
Your first dose of VONVENDI for each bleeding episode may be administered with a recombinant factor VIII as instructed by your healthcare provider.
Your healthcare provider will instruct you whether additional doses of VONVENDI with or without recombinant factor VIII are needed.
What should I tell my healthcare provider before I use VONVENDI?
You should tell your healthcare provider if you:
- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if VONVENDI passes into your milk and if it can harm your baby.
- Are pregnant or planning to become pregnant. It is not known if VONVENDI can harm your unborn baby.
- Have been told that you have inhibitors to von Willebrand factor (because VONVENDI may not work for you).
- Have been told that you have inhibitors to blood coagulation factor VIII.
What else should I know about VONVENDI and von Willebrand Disease?
Your body can form inhibitors to von Willebrand factor or factor VIII. An inhibitor is part of the body’s normal defense system. If you form inhibitors, they may stop VONVENDI or factor VIII from working properly.
Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to von Willebrand factor or factor VIII.
What are the possible side effects of VONVENDI?
You can have an allergic reaction to VONVENDI.
Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.
Side effects that have been reported with VONVENDI include: headache, nausea, vomiting, tingling or burning at infusion site, chest discomfort, dizziness, hot flashes, itching, high blood pressure, muscle twitching, unusual taste, blood clots and increased heart rate.
Tell your healthcare provider about any side effects that bother you or do not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see VONVENDI full Prescribing Information.
©2025 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA Logo are registered trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. VONVENDI is a registered trademark of Baxalta Incorporated. US-VON-1006v1.0 10/25
SOURCE:
Our Lifestyle section on STM Daily News is a hub of inspiration and practical information, offering a range of articles that touch on various aspects of daily life. From tips on family finances to guides for maintaining health and wellness, we strive to empower our readers with knowledge and resources to enhance their lifestyles. Whether you’re seeking outdoor activity ideas, fashion trends, or travel recommendations, our lifestyle section has got you covered. Visit us today at https://stmdailynews.com/category/lifestyle/ and embark on a journey of discovery and self-improvement.
aerospace
Boom Supersonic Update 2026: Overture Progress, XB-1 Milestones, and What’s Next
Boom Supersonic’s 2026 update: XB-1 test success, Overture production timeline, funding progress, and the challenges facing the return of commercial supersonic travel.
By STM Daily News Staff
The race to bring back commercial supersonic travel is accelerating once again, led by Boom Supersonic, a Colorado-based aerospace company aiming to succeed where Concorde left off. As of 2026, the company has achieved meaningful technical milestones—but still faces significant financial, regulatory, and industrial hurdles.
Here’s a comprehensive look at where Boom stands today, and what it means for the future of high-speed air travel.
XB-1 Demonstrator Completes Historic Test Program
Boom’s experimental aircraft, the XB-1, has successfully completed its flight test campaign, marking a critical step toward validating the company’s supersonic technology.
- Achieved multiple supersonic flights in 2025
- Demonstrated aerodynamic stability and performance
- Tested “boomless cruise” capabilities to reduce sonic disturbances
The XB-1 program served as a scaled demonstrator for the company’s flagship commercial jet, proving that modern materials, software, and engine integration can support efficient supersonic flight.
With testing complete, the aircraft is expected to be preserved as a prototype, representing a turning point in private-sector aerospace innovation.
Overture: Boom’s Commercial Supersonic Jet
The centerpiece of Boom’s vision is the Overture, a next-generation supersonic passenger aircraft designed to carry between 60 and 80 passengers at speeds approaching Mach 1.7.
Current projected timeline:
- Prototype rollout: Targeted for 2026
- First flight: Expected around 2027
- Commercial service entry: Late 2020s (estimated 2029–2030)
Unlike Concorde, which catered primarily to elite travelers, Boom aims to position Overture with business-class pricing, potentially expanding access to faster global travel.
The aircraft is also being designed with sustainability in mind, including compatibility with sustainable aviation fuel (SAF).
Funding and Financial Momentum
In recent developments, Boom Supersonic secured an additional $100 million in funding, reinforcing investor confidence in the company’s long-term vision.
However, building a supersonic passenger aircraft remains one of the most capital-intensive challenges in aviation. Continued fundraising and strategic partnerships will be essential as the company moves from prototype to production.
Boomless Cruise: A Potential Game-Changer
One of Boom’s most significant innovations is its focus on “boomless cruise,” a method of flying supersonically without producing an audible sonic boom on the ground.
If proven viable at scale, this technology could influence regulatory changes—particularly in the United States, where overland supersonic flight is currently restricted.
The ability to fly faster-than-sound over land would unlock major domestic routes, dramatically reducing travel times between cities like New York and Los Angeles.
Manufacturing Challenges and Delays
Despite technical progress, Boom’s manufacturing ambitions face uncertainty. A planned production facility in North Carolina has experienced delays, raising questions about when large-scale assembly will begin.
Scaling production from prototype to commercial aircraft remains one of the most difficult phases of any aerospace program, requiring supply chain coordination, workforce development, and regulatory alignment.
Industry Skepticism Remains
While Boom has secured interest from major airlines, skepticism persists within the aviation industry.
Key concerns include:
- Certification complexity and regulatory approval timelines
- Operational costs versus ticket pricing
- Long-term demand for supersonic travel
Even airline executives have expressed cautious optimism, with some suggesting the project’s success remains uncertain.
The Bigger Picture: A Defining Decade for Supersonic Travel
Boom Supersonic has moved beyond concept and into real-world testing, demonstrating that modern supersonic flight is technically achievable.
However, the next phase—bringing Overture to market—will determine whether supersonic passenger travel becomes a viable industry once again or remains an ambitious experiment.
If successful, Boom could redefine global travel times. If not, it will join a long list of bold aerospace ventures that struggled to overcome economic reality.
Sources and External Links
- Boom Supersonic – Year in Review
- XB-1 Aircraft Overview
- Overture Aircraft Specifications
- Funding Announcement
- Industry Perspective
Dive into “The Knowledge,” where curiosity meets clarity. This playlist, in collaboration with STMDailyNews.com, is designed for viewers who value historical accuracy and insightful learning. Our short videos, ranging from 30 seconds to a minute and a half, make complex subjects easy to grasp in no time. Covering everything from historical events to contemporary processes and entertainment, “The Knowledge” bridges the past with the present. In a world where information is abundant yet often misused, our series aims to guide you through the noise, preserving vital knowledge and truths that shape our lives today. Perfect for curious minds eager to discover the ‘why’ and ‘how’ of everything around us. Subscribe and join in as we explore the facts that matter. https://stmdailynews.com/the-knowledge/
The Knowledge
Metrolink Offers Fare-Free Rides for Earth Day 2026 Across Southern California
Metrolink offers fare-free rides for Earth Day 2026 across Southern California, encouraging sustainable travel and reduced emissions.
Last Updated on April 21, 2026 by Daily News Staff
Metrolink Offers Fare-Free Rides for Earth Day 2026
LOS ANGELES — April 22, 2026 — In a continued push toward sustainable transportation, Metrolink will once again offer systemwide free rides on Earth Day, inviting commuters and travelers to leave their cars behind and explore a cleaner way to move across the region.
A One-Day Opportunity to Ride Free
On Wednesday, April 22, passengers can board any Metrolink train — including the Arrow service — without purchasing a ticket. The initiative is part of the broader celebration of Earth Day, encouraging environmentally conscious travel choices.
The fare-free program is designed to appeal to both regular riders and first-time users, particularly those navigating Southern California’s persistent traffic congestion and rising fuel costs.
Encouraging Sustainable Travel Habits
“Earth Day is a reminder that small changes, like choosing public transit over driving one day a week, can have a meaningful impact on our environment,” said Doug Chaffee, chair of the Metrolink Board.
With gas prices continuing to strain household budgets, the agency hopes the initiative will inspire more residents to consider rail as part of their regular commute.
Regional Connections Expand Access
Metrolink’s Earth Day promotion aligns with similar efforts by other Southern California transit providers. Riders can seamlessly connect to services operated by: LA Metro and the Orange County Transportation Authority, Riverside County Transportation Commission, San Bernardino County Transportation Authority and Ventura County Transportation Commission.
These partnerships extend the reach of fare-free travel across a six-county region, making it easier for riders to explore destinations without relying on personal vehicles.
Service Adjustments and Rider Tips
Passengers should note that trains will operate on a reduced weekday schedule, implemented earlier this spring. Despite the adjustment, all Metrolink lines and station cities remain in service.
For those planning a trip:
- No ticket is required — simply board the train
- Bikes are welcome, with capacity ranging from three bikes per standard car to nine in designated bike cars
- A curated destination guide highlights attractions within walking or biking distance of stations
Environmental and Economic Impact
Metrolink is also promoting its Personal Impact Calculator, a digital tool that allows riders to estimate how switching from driving to rail can reduce greenhouse gas emissions and lower fuel expenses.
A Broader Trend in Public Transit
Fare-free transit days have gained traction nationwide as agencies look to boost ridership and promote sustainability. Southern California’s expansive commuter rail network makes it particularly well-suited for such initiatives, offering a viable alternative to one of the country’s most car-dependent regions.
Bottom Line
Metrolink’s Earth Day promotion is more than a one-day free ride — it’s a strategic effort to shift commuter behavior, reduce environmental impact, and showcase the convenience of regional rail. For Southern Californians, April 22 presents a low-risk opportunity to rethink how they travel.
Source: Metrolink
https://metrolinktrains.com/news/metrolink-goes-fare-free-for-earth-day-on-april-22
Dive into “The Knowledge,” where curiosity meets clarity. This playlist, in collaboration with STMDailyNews.com, is designed for viewers who value historical accuracy and insightful learning. Our short videos, ranging from 30 seconds to a minute and a half, make complex subjects easy to grasp in no time. Covering everything from historical events to contemporary processes and entertainment, “The Knowledge” bridges the past with the present. In a world where information is abundant yet often misused, our series aims to guide you through the noise, preserving vital knowledge and truths that shape our lives today. Perfect for curious minds eager to discover the ‘why’ and ‘how’ of everything around us. Subscribe and join in as we explore the facts that matter. https://stmdailynews.com/the-knowledge/
Science
New Glenn’s Third Mission Set for April 19 as Blue Origin Advances Commercial Space Capabilities
CAPE CANAVERAL, Fla. — Blue Origin has confirmed the launch window for the third mission of its heavy-lift New Glenn rocket, marking another step forward in the company’s expanding role in commercial spaceflight.
New Glenn’s Third Mission
Launch Details and Timeline
The mission is scheduled to lift off no earlier than Sunday, April 19, 2026, from Launch Complex 36 at Cape Canaveral Space Force Station. The two-hour launch window opens at 6:45 a.m. EDT (10:45 UTC) and closes at 8:45 a.m. EDT (12:45 UTC).
Viewers can follow the mission through a live webcast hosted by Blue Origin, beginning approximately 30 minutes before liftoff.
Mission Payload: Expanding Space-Based Connectivity
At the heart of the mission is the deployment of the BlueBird 7 satellite, developed by AST SpaceMobile. The satellite is designed to enhance a growing direct-to-smartphone broadband network, an emerging technology aimed at delivering connectivity to standard mobile devices without the need for ground-based towers.
BlueBird 7 will contribute to expanding network capacity and is expected to support initial service rollout plans targeted for 2026. The broader initiative reflects a significant shift in how satellite infrastructure could complement terrestrial telecom systems, particularly in underserved or remote regions.
Reusability Milestone: Booster Returns Again
A key feature of this mission is the planned reuse of New Glenn’s first-stage booster, “Never Tell Me The Odds.” The booster previously demonstrated a successful launch and landing during the rocket’s second mission in November, underscoring Blue Origin’s commitment to reusable rocket technology—a cornerstone of cost reduction and operational efficiency in modern spaceflight.
If successful, this mission will further validate the reliability of the New Glenn system and strengthen its competitiveness in a market increasingly shaped by reusable launch vehicles.
Industry Context: Competing in a Rapidly Evolving Market
The New Glenn program represents Blue Origin’s answer to heavy-lift launch demands, positioning the company alongside major players such as SpaceX. As satellite constellations grow in scale and ambition, reliable and cost-effective launch services have become a critical component of the global space economy.
The inclusion of commercial payloads like BlueBird 7 highlights the increasing collaboration between aerospace firms and telecommunications providers, signaling a future where space-based infrastructure plays a central role in everyday connectivity.
Looking Ahead
With its third mission, New Glenn continues to build momentum as a next-generation launch platform. The combination of reusable hardware, commercial partnerships, and advanced payload capabilities places this launch among the most closely watched developments in the 2026 spaceflight calendar.
For ongoing updates, mission tracking, and live coverage, audiences can follow Blue Origin across its digital platforms or visit its official website.
Source
Blue Origin Official Announcement – New Glenn Third Mission
Related External Links
- Learn More About Blue Origin’s New Glenn Rocket
- AST SpaceMobile – Space-Based Cellular Broadband Network
- Cape Canaveral Space Force Station Information
- NASA Overview of Low Earth Orbit (LEO) Operations
Explore the latest in innovation, AI, gadgets, startups, and digital trends in STM Daily News’ Techsection.
